

September 10, 2014



## Aethlon Medical, Inc. Launches Digital Corporate Communication Channels

SAN DIEGO and NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Aethlon Medical, Inc., (NASDAQ:OTCQB: AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.



The Chairman's Blog is an online communication portal where Aethlon Medical executives can address important topics as they relate to infectious disease, cancer and other life threatening conditions as well as specific points of discussion as they relate to key events at Aethlon Medical. Chairman and Chief Executive Officer James A. Joyce penned his inaugural blog post, "[The Ebola, Dengue, Enterovirus, and Chikungunya Outbreaks](#)." The blog post can be found online at the official Aethlon Medical Chairman's Blog profile provided below.

Links to the new communication tools are here:

Facebook: <https://www.facebook.com/aethlonmedical>

Twitter: [https://twitter.com/Aethlon\\_Medical](https://twitter.com/Aethlon_Medical)

LinkedIn: <https://www.linkedin.com/company/807934>

Google+: <https://plus.google.com/u/1/b/117891658199563877043/117891658199563877043>

The Chairman's Blog: <http://www.thechairmansblog.com/aethlon-medical/>

## **About Aethlon Medical, Inc.**

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at [www.AethlonMedical.com](http://www.AethlonMedical.com).

## **About TheChairmansBlog.com**

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. [www.thechairmansblog.com](http://www.thechairmansblog.com)

*Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.*

Contacts:

James A. Joyce

Chairman and CEO

858.459.7800 x301

[jj@aethlonmedical.com](mailto:jj@aethlonmedical.com)

Jim Frakes  
Chief Financial Officer  
858.459.7800 x300  
[jfrakes@aethlonmedical.com](mailto:jfrakes@aethlonmedical.com)



Photo - <https://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b>

Logo - <https://photos.prnewswire.com/prnh/20130912/LA78266LOGO>

SOURCE Aethlon Medical, Inc.